Alpha Tau Medical (NASDAQ:DRTS) Stock Rating Reaffirmed by HC Wainwright

Alpha Tau Medical (NASDAQ:DRTS)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They currently have a $9.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 309.09% from the stock’s previous close.

Separately, Piper Sandler reissued an “overweight” rating and issued a $7.00 price objective on shares of Alpha Tau Medical in a research note on Thursday, August 15th.

Alpha Tau Medical Price Performance

Alpha Tau Medical stock opened at $2.20 on Friday. The company has a current ratio of 11.66, a quick ratio of 11.60 and a debt-to-equity ratio of 0.07. Alpha Tau Medical has a 12-month low of $1.75 and a 12-month high of $3.90. The stock has a market cap of $153.28 million, a P/E ratio of -5.37 and a beta of 0.77. The company has a fifty day simple moving average of $2.26 and a 200-day simple moving average of $2.38.

Alpha Tau Medical (NASDAQ:DRTS) last announced its earnings results on Wednesday, August 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. Equities analysts expect that Alpha Tau Medical will post -0.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Alpha Tau Medical

Institutional investors and hedge funds have recently modified their holdings of the company. USAdvisors Wealth Management LLC purchased a new position in shares of Alpha Tau Medical during the 1st quarter worth $30,000. Aptus Capital Advisors LLC lifted its holdings in Alpha Tau Medical by 83.7% in the 2nd quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company’s stock worth $56,000 after buying an additional 10,000 shares in the last quarter. Financial Guidance Group Inc. boosted its position in Alpha Tau Medical by 83.7% in the 2nd quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company’s stock valued at $56,000 after buying an additional 10,000 shares during the last quarter. Caprock Group LLC acquired a new position in shares of Alpha Tau Medical in the 2nd quarter valued at approximately $59,000. Finally, Levin Capital Strategies L.P. increased its position in shares of Alpha Tau Medical by 2.6% in the 1st quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company’s stock worth $999,000 after purchasing an additional 8,641 shares during the last quarter. Institutional investors and hedge funds own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.